Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid Leukemia
Complete Title: A phase 2 trial of fractionated gemtuzumab ozogamicin to eradicate measurable residual disease in acute myeloid leukemia patients (GO for MRD)
Trial Phase: II
Investigator: Mary-Elizabeth Percival
This phase II trial studies how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in participants with acute myeloid leukemia. Antibody-drug conjugates, such as gemtuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells.
Keywords:
- Leukemia, Acute Myeloid (AML)
- Leukemia
- Neoplastic Processes
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
II
Mary-Elizabeth Percival
9966
NCT03737955
A phase 2 trial of fractionated gemtuzumab ozogamicin to eradicate measurable residual disease in acute myeloid leukemia patients (GO for MRD)
Leukemia, Acute Myeloid (AML)
Leukemia
Neoplastic Processes